Skip to main content
Abiraj Keelara on Muck Rack

Abiraj Keelara

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Abiraj

Contact Abiraj, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

|
By Martin Hutchings, Michael H. Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, William D. Townsend, Francesc Bosch, Nancy L. Bartlett, Guillaume Cartron, Herve Ghesquieres, Roch Houot, Harriet Walter, Fritz Offner, Natalie Dimier, Candice Jamois, Sylvia Herter, Sabine Wilson, Heather Hinton, Koorosh Korfi, Georgios Kazantzidis, Katharina Lechner, Franck Morschhauser, Abiraj Keelara, Jeremy Gallien, Isabel Prieto Gonzalez-Albo, Marie-Hélène Wasmer
| Nature Verified
Abstract There is an unmet need for effective, off-the-shelf therapies for relapsed or refractory aggressive B cell non-Hodgkin lymphoma (B-NHL). Part 2 of the current study was an open-label, nonrandomized, phase 1 study of escalating doses of the CD19–4-1BBL co-stimulatory molecule, englumafusp alfa, in combination with glofitamab in patients with relapsed or refractory B-NHL. Obinutuzumab pretreatment was administered 7 days before the first glofitamab dose.
Open in Who Shared Issue with article?
See all 1 articles